NEW YORK (GenomeWeb) – Illumina said at the close of the market on Tuesday that sales of its HiSeq X Ten and NextSeq 500 instruments helped drive record revenues of $512.4 million in the fourth quarter of 2014.

During a conference call discussing the company's 2014 fourth quarter and full-year results, CEO Jay Flatley provided an update of the company's sequencing and array businesses, discussed a future liquid biopsy oncology product, and gave an update on its noninvasive prenatal testing business and progress with the US Food and Drug Administration on developing a cleared NIPT.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.